Chonglei Bi

No. 12-02, 14 Medical Drive
Singapore, 117599, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.

Journal: Oncotarget
Published: March 28, 2017

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.

Journal: Journal of hematology & oncology
Published: February 03, 2017

Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.

Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.

Journal: Molecular oncology
Published: December 27, 2016

LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.

LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.

Journal: Molecular cancer research : MCR
Published: August 11, 2016

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.

Journal: Oncotarget
Published: May 05, 2016

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.

Journal: Blood
Published: January 05, 2016

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Journal: Oncotarget
Published: October 19, 2015

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Journal: Oncotarget
Published: April 16, 2015

MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.

MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.

Journal: Leukemia
Published: April 09, 2015

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

Journal: Molecular cancer therapeutics
Published: January 22, 2015

Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.

Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.

Journal: Experimental hematology
Published: March 29, 2014

MicroRNA: important player in the pathobiology of multiple myeloma.

MicroRNA: important player in the pathobiology of multiple myeloma.

Journal: BioMed research international
Published: March 26, 2014
Showing 1-12 of 17

Last Updated: 09/26/2026